Medincell S.A (MEDCL) | Financial Analysis & Statements
Medincell S.A. | Mid-cap | Healthcare
Medincell S.A. | Mid-cap | Healthcare
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
9.2M
Gross Profit
9.2M
100.00%
Operating Income
-21.0M
-228.98%
Net Income
-25.0M
-273.34%
EPS (Diluted)
-€0.88
Balance Sheet Metrics
Total Assets
36.9M
Total Liabilities
77.8M
Shareholders Equity
-40.8M
Cash Flow Metrics
Operating Cash Flow
-12.6M
Free Cash Flow
-13.1M
Revenue & Profitability Trend
Medincell S.A Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 9.2M | 9.9M | 4.1M | 8.2M | 2.9M |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 969.0K |
| Gross Profit | 9.2M | 9.9M | 4.1M | 8.2M | 1.9M |
| Operating Expenses | 25.3M | 31.3M | 26.4M | 22.0M | 26.9M |
| Operating Income | -21.0M | -24.0M | -23.8M | -15.6M | -19.3M |
| Pre-tax Income | -25.0M | -32.0M | -24.8M | -19.0M | -21.4M |
| Income Tax | 88.0K | 0 | 0 | 0 | 2.5M |
| Net Income | -25.0M | -32.0M | -24.8M | -19.0M | -23.9M |
| EPS (Diluted) | -€0.88 | -€1.27 | -€1.00 | -€0.86 | -€1.19 |
Income Statement Trend
Medincell S.A Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 27.3M | 19.6M | 34.1M | 56.3M | 17.7M |
| Non-Current Assets | 9.7M | 9.8M | 10.2M | 7.3M | 9.6M |
| Total Assets | 36.9M | 29.3M | 44.3M | 63.6M | 27.3M |
| Liabilities | |||||
| Current Liabilities | 16.5M | 57.0M | 38.2M | 13.6M | 6.6M |
| Non-Current Liabilities | 61.3M | 14.6M | 19.4M | 40.9M | 36.7M |
| Total Liabilities | 77.8M | 71.6M | 57.7M | 54.5M | 43.3M |
| Equity | |||||
| Total Shareholders Equity | -40.8M | -42.3M | -13.4M | 9.1M | -16.0M |
Balance Sheet Composition
Medincell S.A Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -25.0M | -32.0M | -24.8M | -19.0M | -23.9M |
| Operating Cash Flow | -12.6M | -24.9M | -23.0M | -13.4M | -18.0M |
| Investing Activities | |||||
| Capital Expenditures | -323.0K | -528.0K | -1.6M | -645.0K | -575.0K |
| Investing Cash Flow | -323.0K | -528.0K | -1.6M | -645.0K | -607.0K |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 28.4M | 6.6M | 857.0K | 51.7M | 5.3M |
| Free Cash Flow | -13.1M | -22.0M | -23.3M | -13.0M | -13.4M |
Cash Flow Trend
Medincell S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-18.81
Forward P/E
85.50
Price to Sales
20.39
PEG Ratio
85.50
Profitability Ratios
Profit Margin
-66.50%
Operating Margin
-17.30%
Return on Equity
61.33%
Return on Assets
-67.77%
Financial Health
Current Ratio
1.66
Debt to Equity
-1.44
Beta
1.08
Per Share Data
EPS (TTM)
-€1.09
Book Value per Share
-€1.86
Revenue per Share
€0.32
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| medcl | 565.5M | -18.81 | - | 61.33% | -66.50% | -1.44 |
| Valneva SE | 409.5M | 70.64 | 2.11 | -44.11% | -43.21% | 120.48 |
| BNP Paribas Easy | 456.7M | 15.91 | - | -96.39% | -27.22% | 2.22 |
| Abivax SA | 331.7M | -1.96 | -52.78 | -196.12% | 0.00% | -16.16 |
| Inventiva S.A | 379.0M | -0.88 | -0.99 | 172.73% | 0.00% | -1.70 |
| Viridian | 415.4M | 50.43 | 0.40 | 0.93% | 2.05% | 103.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.